ARNA Financial Facts
General and administrative: 8.59MCollaborative agreements: 12.95M
See Full Income Statement
Deferred revenues, less current portion: 82.13M
Accumulated deficit: -1.44B
See Full Balance Sheet
Arena Pharmaceuticals, Inc. (ARNA) Earnings
|
Expand Research on ARNA
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -6.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -7.6% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/8/19 |  |
Q119 | $12.10 | $13.89 | -$1.79 | $801.1M | $801.7M | N/A |  | | Details |
| 3/14/17 | Q416 | $0.16 | -$0.08 | +$0.24 | $85.4M | $15.58M | = | | | Details | |
8/1/13  |
Q213 | $0.18 | $0.15 | +$0.03 | $68.9M | $57.3M | N/A | | | Details | |
| 8/9/12 |
|
Q212 | -$0.12 | -$0.08 | -$0.04 | $22M | $7.38M | N/A | | | Details |
| 11/7/16 |
|
Q316 | -$0.05 | -$0.07 | +$0.02 | $19M | $13.99M | N/A | | | Details |
| 3/14/18 | |
Q417 | -$0.35 | -$0.59 | +$0.24 | $15.4M | $7.57M | = | | | Details |
| 8/1/14 | Q214 | $0.03 | -$0.11 | +$0.14 | $12.8M | $9.81M | N/A | | | Details | |
| 5/11/15 |
|
Q115 | -$0.10 | -$0.14 | +$0.04 | $12.3M | $10.56M | N/A | | | Details |
